News & Updates

Show Multimedia Only

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

14 Jan 2026

In the treatment of patients with advanced soft-tissue sarcoma, combining anlotinib with anthracyclines and ifosfamide in the first-line setting followed by anlotinib maintenance has demonstrated promising efficacy, with acceptable toxicities, in a phase II study.

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

14 Jan 2026

Metastasis-directed SBRT alone may be enough for patients with oligometastatic disease

13 Jan 2026 by

Metastasis-directed stereotactic body radiotherapy (SBRT) alone can delay the need for systemic therapy in some patients with oligometastatic cancer, with low risks of treatment-related adverse events, according to a meta-analysis.

Metastasis-directed SBRT alone may be enough for patients with oligometastatic disease

13 Jan 2026

Patient fatigue flags risk of toxicity from cancer treatment

10 Jan 2026 by

Patient fatigue reported before the initiation of cancer treatment appears to be associated with an increased risk of subsequent treatment-related adverse events, according to new research.

Patient fatigue flags risk of toxicity from cancer treatment

10 Jan 2026

T-DXd plus RT shows promise in management of metastatic breast cancer

09 Jan 2026

Combination treatment with trastuzumab deruxtecan (T-DXd) and radiation therapy (RT) may improve clinical outcomes, without compromising safety, in patients with HER2-positive and HER2-low metastatic breast cancer, reveals a study.

T-DXd plus RT shows promise in management of metastatic breast cancer

09 Jan 2026

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

09 Jan 2026 by

The results from the phase III ROP-ET trial demonstrate the potential of ropeginterferon alfa-2b (ropeg) for the treatment of essential thrombocythaemia (ET) across all risk levels in patients who are ineligible for standard cytoreduction.

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

09 Jan 2026

OAB symptoms may increase in breast cancer patients undergoing chemotherapy

08 Jan 2026

Symptoms of overactive bladder (OAC) tend to rise among women receiving both trastuzumab and pertuzumab for HER2-positive positive breast cancer during their treatment, reports a study.

OAB symptoms may increase in breast cancer patients undergoing chemotherapy

08 Jan 2026

Tamoxifen interruption for pregnancy feasible in young breast cancer survivors

08 Jan 2026 by

A real-world Asian study presented at ESMO Asia 2025 supports temporary tamoxifen interruption for young breast cancer survivors who are considering pregnancy.

Tamoxifen interruption for pregnancy feasible in young breast cancer survivors

08 Jan 2026

Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6

06 Jan 2026 by

In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).

Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6

06 Jan 2026

Follow-up care a must for late effects in childhood cancer survivors

05 Jan 2026 by

Timely screening is needed to enhance early detection of metabolic health, bone health, and hearing impairment among childhood cancer survivors treated in Singapore, suggests a recent study. Adoption of an exposure-based approach to proactively screen for late effects can reduce biopsychosocial impacts.

Follow-up care a must for late effects in childhood cancer survivors

05 Jan 2026

Original New Drug Application Approvals by US FDA (16-30 November 2025)

05 Jan 2026

New drug applications approved by US FDA as of 16-30 November 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 November 2025)

05 Jan 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

Metastasis-directed SBRT alone may be enough for patients with oligometastatic disease

Metastasis-directed SBRT alone may be enough for patients with oligometastatic disease

Patient fatigue flags risk of toxicity from cancer treatment

Patient fatigue flags risk of toxicity from cancer treatment

T-DXd plus RT shows promise in management of metastatic breast cancer

T-DXd plus RT shows promise in management of metastatic breast cancer

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

OAB symptoms may increase in breast cancer patients undergoing chemotherapy

OAB symptoms may increase in breast cancer patients undergoing chemotherapy

Tamoxifen interruption for pregnancy feasible in young breast cancer survivors

Tamoxifen interruption for pregnancy feasible in young breast cancer survivors

Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6

Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6

Follow-up care a must for late effects in childhood cancer survivors

Follow-up care a must for late effects in childhood cancer survivors

Original New Drug Application Approvals by US FDA (16-30 November 2025)

Original New Drug Application Approvals by US FDA (16-30 November 2025)